ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]
ARS Pharmaceuticals (SPRY) was upgraded by Zacks Research from "strong sell" to "hold".
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock [Seeking Alpha]
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting